Skip to content
中文产业新闻精选评分68Chinese source

PICC-2研究：特瑞普利单抗联合塞来昔布新辅助治疗dMMR/MSI-H局晚期结直肠癌pCR率达89%

Lancet Oncology丨邓艳红教授团队新辅助免疫联合策略突破，dMMR/MSI-H局晚期结直肠癌pCR率达89%

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.